GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches

Therapeutics against coronavirus disease 2019 (COVID-19) are urgently needed. Granulocyte–macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor and pro-inflammatory cytokine, plays a critical role in alveolar macrophage homeostasis, lung inflammation and immunological disease....

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Frederick M., Lee, Kevin M.-C., Teijaro, John R., Becher, Burkhard, Hamilton, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309428/
https://www.ncbi.nlm.nih.gov/pubmed/32576980
http://dx.doi.org/10.1038/s41577-020-0357-7
Descripción
Sumario:Therapeutics against coronavirus disease 2019 (COVID-19) are urgently needed. Granulocyte–macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor and pro-inflammatory cytokine, plays a critical role in alveolar macrophage homeostasis, lung inflammation and immunological disease. Both administration and inhibition of GM-CSF are currently being therapeutically tested in COVID-19 clinical trials. This Perspective discusses the pleiotropic biology of GM-CSF and the scientific merits behind these contrasting approaches.

Ejemplares similares